Two injections, two completely different jobs

Choosing between ChondroFiller and hyaluronic acid (HA) is not a question of which injection is stronger or longer-lasting — it is a question of what problem actually needs solving.

HA works by restoring viscosity to the synovial fluid that surrounds the joint. Think of it as replenishing the natural lubricant: friction reduces, movement feels easier, and pain often settles for months at a time. What it cannot do is fill or structurally repair a discrete hole in the cartilage surface.

ChondroFiller does something fundamentally different. It places an acellular Type I collagen scaffold directly at the defect site, where it gels within minutes and acts as a chemotactic matrix — drawing the patient's own progenitor cells in to support the body's own repair processes through acellular matrix-induced chondrogenesis. That is biological repair, not lubrication.

A recognised clinical hierarchy captures this plainly: HA addresses lubrication; ChondroFiller addresses structural repair. They occupy different rungs of the treatment ladder because they target different problems.

The practical consequence is that the choice between them is driven by eligibility rather than patient preference — and that eligibility hinges on whether there is a focal, localised cartilage lesion or a pattern of more generalised wear.

What each injection does inside the joint

The distinction becomes clearer when you follow what each product does in the hours, days, and months after injection.

Hyaluronic acid supplements thinned synovial fluid — the joint's natural lubricant and shock-absorber — increasing its viscosity so that cartilage surfaces move against one another with less friction. Relief typically lasts three to six months per course; repeat injections are safe and practical, usually given roughly every six months as needed. Clinical guideline bodies differ on HA's overall merits: OARSI offers conditional support, while both the AAOS and ACR are more sceptical, reflecting variable results across different trial populations. Importantly, HA does not fill or structurally bridge a focal defect in the cartilage surface at any point during that cycle.

ChondroFiller operates on a different biological timeline. Once the scaffold is placed at the defect site under ultrasound guidance, it sets at body temperature within a few minutes — and then begins a slower process of cell recruitment. A 2025 ex vivo study measured a 2.4-fold increase in DNA content within the scaffold by day 14, providing direct evidence that the body's own repair cells migrate into the matrix rather than simply around it. This confirms mechanism — it does not establish full cartilage restoration — but it demonstrates the scaffold is biologically active rather than inert. Over the following twelve to twenty-four months the scaffold resorbs progressively, as the patient's own maturing tissue gradually replaces it. That makes ChondroFiller a single-course biological intervention, not a repeating palliative cycle.

Which patients suit each option

Diagnosis determines the path here — symptoms alone cannot tell a clinician which injection is appropriate.

ChondroFiller is suited to patients with a confirmed focal, isolated cartilage defect, typically up to approximately 3 cm² in area, in a joint that is otherwise structurally stable. That means no advanced bone-on-bone osteoarthritis, no untreated ligament instability, and no significant malalignment. Where those mechanical conditions are not met, the scaffold cannot function as intended and ChondroFiller is not appropriate, regardless of how severe the patient's symptoms are.

Hyaluronic acid carries no equivalent structural gate. It suits patients with generalised cartilage wear, early-to-moderate osteoarthritis, or symptoms that arise from joint-wide changes rather than a discrete lesion. For many patients in that category, HA is a sensible, accessible first step.

The more complex picture arises when a patient has a focal defect against a background of mild, generalised OA — a combination that is not uncommon. In those cases the choice is rarely binary; a specialist review is needed to weigh whether the focal lesion is the primary pain driver and whether the broader joint environment is stable enough for repair therapy to succeed.

MRI is the prerequisite for any of this. Defect size, depth, location, and the state of surrounding cartilage and bone all inform suitability for ChondroFiller — and without a current, interpreted scan, that suitability cannot be established. A thorough consultant-led review of imaging is the starting point, not an optional step.

What the clinical evidence shows

Published data for ChondroFiller centres on the International Knee Documentation Committee (IKDC) score — a validated patient-reported measure of knee function. Across four knee-specific clinical studies, patients consistently recorded improvements of approximately 30 points from baseline, well above the 16.7-point Minimal Clinically Important Difference (MCID) — the threshold at which a change is considered meaningful rather than statistical noise. The most detailed follow-up comes from the Jerosch et al. prospective post-market clinical follow-up study, in which a mean IKDC gain of 32.4 points was sustained — and marginally increased — at three years, with patients reaching a mean functional score of 80.

MRI-based MOCART scoring in European studies adds a structural dimension: scores of 81.6 to 84.3 at twelve months indicate that more than 80% of the defect is filled, with good integration into the surrounding native cartilage. MOCART rose from 65.3 at four weeks to 81.6 at one year, reflecting progressive repair maturation rather than immediate structural change. Patient-reported success across the available data ranges from 70–85%, with approximately 80% rating their result good or very good.

That picture carries important caveats. No published head-to-head randomised controlled trial compares ChondroFiller directly against HA for focal cartilage defects — the two evidence bases run in parallel rather than against each other. Most ChondroFiller data is observational or manufacturer-associated; independent large-scale replication remains limited. The 70–85% success figure also lacks a standardised comparator, which makes cross-study interpretation cautious work.

For HA, the evidence base is wider but differently targeted: it reliably reduces symptoms in osteoarthritis populations, with guideline bodies split on the size of that benefit. What HA does not do — in any published dataset — is structurally alter a focal defect. That is not a failure of the product; it simply confirms that it addresses a different problem.

How each treatment is given

Both treatments are given as outpatient injections — no theatre admission, no general anaesthetic, no surgical incision for either option.

For hyaluronic acid, the product is injected directly into the joint space, typically in a single session or across a short multi-injection course depending on the formulation. A course generally provides relief for around six months, after which repeat treatment is straightforward. HA is available through the NHS and most private medical insurance plans.

ChondroFiller is placed under ultrasound guidance as an injectable collagen scaffold, delivered precisely at the focal defect site in a single outpatient appointment. The gel forms in situ within minutes of placement, and — because the scaffold then recruits the patient's own cells progressively over the following months — a single treatment course is the intended approach rather than regular repeat injections. ChondroFiller is currently a self-funded private treatment in the UK; guide costs are confirmed by the treating clinic at assessment.

Patients can be assessed at MSK Doctors in Sleaford, Lincolnshire and Grantham without a GP referral, with no NHS-style waiting list — a practical starting point for those across the non-London catchment who want a consultant-led opinion on which option suits their specific joint.

Getting the right answer for your knee

The practical starting point is a current MRI. Defect size, depth, and location — alongside the condition of the surrounding cartilage and subchondral bone — all shape which pathway is clinically appropriate. A scan taken more than twelve months ago, or one performed for a different clinical purpose, may not carry enough detail for a consultant to advise with confidence.

With good imaging in hand, the clinical conversation becomes more focused. Is there a discrete focal lesion, or wear distributed across multiple compartments? Is the joint mechanically stable? What is the grade of the surrounding cartilage? Those specific findings place a patient in the correct part of the decision framework far more precisely than symptoms alone — and they are the questions worth raising at a specialist appointment.

For a confirmed focal defect in a mechanically stable joint, ChondroFiller is a logical pathway to explore at consultation. For generalised osteoarthritic wear without a discrete lesion, HA or another injection option is likely more appropriate. Where both patterns coexist — a focal defect against a background of mild OA — that is exactly the kind of mixed picture that warrants specialist review rather than a self-directed product choice.

MSK Doctors consultants in Sleaford and Grantham offer imaging review and injection pathway assessment without a GP referral; appointments can be arranged online at mskdoctors.com.